NANOPHARMACEUTICALS have been at the bench level for decades, despite often compelling data about lower dosing, solving insoluble API issues, getting increased dissolution, and higher bioavailability. As Elan’s dominant nano IP has been expiring, and which launched the most marketed nano drugs, there are no obvious contenders in this space today. Elan’s business model had fees that excluded all early stage Biopharma companies. There is room for a new entrant with a different model.
http://lnkd.in/–VJGn
linkedin post 2022-06-29 05:12:48
Nigel Fleming
September 21, 2022